Biodefense Market Analysis By Product (Anthrax, Smallpox, Botulism, Radiation/Nuclear, Ebola, Hemorrhagic Fever) And Segment Forecasts To 2020

Published: Jan, 2015 | Pages: 77 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Global biodefense market is expected to reach USD 13.33 billion by 2020. Growing R&D investments in the field of biotechnology coupled with increasing threat of bioterrorism and disease outbreaks is expected to drive market growth during the forecast period. Furthermore, presence of favorable government initiatives for instance the Emergency Use Authorization (EUA) is expected to boost market growth. This provision allows products to be marketed without an FDA approval in an emergency. Initiatives undertaken by the governments of developing nations for strengthening their respective biodefense product portfolio is expected to fuel future market growth.

Biodefense against anthrax accounted for the largest market share owing to its inclusion in the class A highest priority pathogen category. This classification has resulted in the presence of extensive R&D investments aimed at new product development for strengthening national stockpiles. The global biodefense against anthrax was valued at over USD 2.0 billion in 2013.

Further key findings from the study suggest:

North American was the most revenue generating region in 2013. Majority of the funding programs are organized by the U.S. based government and private establishments. Moreover, these establishments cater to procurement needs of foreign markets.
The market is majorly governed by the initiatives undertaken in the U.S. The country is the largest revenue contributor and is expected to maintain its market position throughout the forecast period. Moreover, funding received by manufacturers under projects such as BioShield is expected to significantly boost demand over the next six years.
Developed European countries such as Germany and the UK have designated funding policies in place pertaining to biodefense. In Switzerland, there is no set biodefense definition but the NBC (nuclear, biological, chemical) protection and research is carried out in Spiez Laboratory of Federal office for Civil Protection, within the Federal Department of Defense. A total of 12 civilian facilities operate under the Swiss biodefense program.
Key players of this market include Emergent BioSolutions, SIGA Technologies, Xoma Corporation and PharmAthene.
Mergers and acquisitions and participating in government tenders are two key sustainability strategies adopted by market players. For instance, in December, 2014, Emergent BioSolutions announced that it had acquired the EV-035 series of molecules from Evolva Holding SA. The acquisition will further strengthen the company's biodefense line of products.
For the purpose of this study, Grand View Research has segmented the global biodefense market on the basis of product and region:

Global Biodefense Product Outlook (Revenue, USD Million, 2012 - 2020)
Anthrax
Smallpox
Botulism
Radiation/Nuclear defense
Others
Biodefense Regional Outlook (Revenue, USD Million, 2012 - 2020)
North America
U.S.
Canada
Europe
Germany
UK
Asia Pacific
Japan
China
RoW
Brazil

 Table of Contents


Chapter 1 Executive Summary
Chapter 2 Biodefense Industry Outlook
                2.1 Market Segmentation
                2.2 Market size and growth prospects
                2.3 Biodefense - Market dynamics
                    2.3.1 Market driver analysis
                        2.3.1.1 Presence of favorable government initiatives
                            2.3.1.1.1 Emergency Use Authorization of Medical Products
                            2.3.1.1.2 Project BioShield Act
                    2.3.2 Market Restraint Analysis
                        2.3.2.1 Low market penetration in developing and underdeveloped countries
                2.4 Key Opportunities Prioritized
                2.6 Biodefense - PESTEL analysis
                2.7 Market scenario by type
                    2.7.1 Biological Defense
                    2.7.2 Chemical Defense
                        2.7.2.1 Chemical defense: Product pipeline
                    2.7.3 Nuclear/Radiological Defense
                        2.7.3.1 Nuclear/radiological defense: Product pipeline analysis
Chapter 3 Biodefense Product Outlook
                3.1 Biodefense market share by product, 2013 & 2020
                3.2 Anthrax
                    3.2.1 Biodefense against anthrax market, 2012 - 2020 (USD Million)
                3.3 Smallpox
                    3.3.1 Biodefense against smallpox market, 2012 - 2020 (USD Million)
                3.4 Botulism
                    3.4.1 Biodefense against botulism market, 2012 - 2020 (USD Million)
                3.5 Radiation/ nuclear defense
                    3.5.1 Biodefense against radiation/nuclear defense market, 2012 - 2020 (USD Million)
                3.6 Others
                    3.6.1 Biodefense against other threats market, 2012 - 2020 (USD Million)
Chapter 4 Biodefense Regional Outlook
                4.1 Biodefense market share by region, 2013 & 2020
                4.2 North America
                    4.2.1 North America biodefense market, 2012 - 2020 (USD Million)
                    4.2.2 U.S. biodefense market, 2012 - 2020 (USD Million)
                    4.2.3 U.S. biodefense market,2012-2020 (USD Million)
                        4.2.3.1 U.S. biodefense market, by scenario, 2012 - 2020 (USD Million)
                    4.2.4 U.S. biodefense market, by source, 2012 - 2020 (USD Million)
                        4.2.4.1 Federal Agencies
                            4.2.4.1.1 BioShield Act
                            4.2.4.1.2 Department of Health and Human Services (HHS)
                            4.2.4.1.3 Department of Defense (DoD)
                            4.2.4.1.4 Department of Homeland Security
                            4.2.4.1.5 Department of Agriculture
                            4.2.4.1.6 Environmental Protection Agency
                            4.2.4.1.7 Department of Commerce
                        4.2.4.2 Other Agencies
                    4.2.5 Canada biodefense market, 2012 - 2020 (USD Million)
                4.3 Europe
                    4.3.1 Europe biodefense market, 2012-2020 (USD Million)
                    4.3.2 Germany biodefense market, by product,2012-2020(USD Million)
                    4.3.3 Germany biodefense market, 2012-2020 (USD Million)
                    4.3.4 UK biodefense market, by product, 2012-2020 (USD Million)
                    4.3.5 UK biodefense market, 2012-2020 (USD Million)
                4.4 Asia Pacific
                    4.4.1 Asia Pacific biodefense market, 2012-2020 (USD Million)
                    4.4.2 Japan biodefense market, 2012-2020 (USD Million)
                    4.4.3 Japan biodefense market, 2012-2020(USD Million)
                    4.4.4 China biodefense market, 2012-2020 (USD Million)
                4.5 RoW
                    4.5.1 RoW biodefense market, 2012-2020 (USD Million)
Chapter 5 Competitive Landscape
                5.1 Xoma Corporation
                    5.1.1 Company Overview
                    5.1.2 Financial Performance
                    5.1.3 Product Benchmarking
                    5.1.4 Strategic Initiatives
                5.2 PharmAthene
                    5.2.1 Company Overview
                    5.2.2 Financial Performance
                    5.2.3 Product Benchmarking
                    5.2.4 Strategic Initiatives
                5.3 Emergent Biosolutions
                    5.3.1 Company Overview
                    5.3.2 Financial Performance
                    5.3.3 Product Benchmarking
                    5.3.4 Strategic Initiatives
                5.4 Dynavax Technologies Inc.
                    5.4.1 Company Overview
                    5.4.2 Financial Performance
                    5.4.3 Product Benchmarking
                    5.4.4 Strategic Initiatives
                5.5 SIGA Technologies
                    5.5.1 Company Overview
                    5.5.2 Financial Performance
                    5.5.3 Product Benchmarking
                    5.5.4 Strategic Initiatives
                5.6 Elusys Therapeutics
                    5.6.1 Company Overview
                    5.6.2 Financial Performance
                    5.6.3 Product Benchmarking
                    5.6.4 Strategic Initiatives
                5.7 Ichor Medical Systems Inc.
                    5.7.1 Company Overview
                    5.7.2 Financial Performance
                    5.7.3 Product Benchmarking
                    5.7.4 Strategic Initiatives
                5.8 DynPort Vaccine Company LLC
                    5.8.1 Company Overview
                    5.8.2 Financial Performance
                    5.8.3 Product Benchmarking
                    5.8.4 Strategic Initiatives
                5.9 Cleveland BioLabs, Inc.
                    5.9.1 Company Overview
                    5.9.2 Financial Performance
                    5.9.3 Product Benchmarking
                    5.9.4 Strategic Initiatives
                5.10 Bavarian Nordic
                    5.10.1 Company Overview
                    5.10.2 Financial Performance
                    5.10.3 Product Benchmarking
                    5.10.4 Strategic Initiatives
                5.11 Achaogen
                    5.11.1 Company Overview
                    5.11.2 Financial Performance
                    5.11.3 Product Benchmarking
                    5.11.4 Strategic Initiatives
                5.12 Nanotherapeutics, Inc.
                    5.12.1 Company Overview
                    5.12.2 Financial Performance
                    5.12.3 Product Benchmarking
                    5.12.4 Strategic Initiatives
                5.13 Alnylam Pharmaceuticals
                    5.13.1 Company Overview
                    5.13.2 Financial Performance
                    5.13.3 Product Benchmarking
                5.14 Major list of biodefense contracts, by market player
Chapter 6 Methodology and Scope
                6.1 Research Methodology
                6.2 Research Scope & Assumptions
                6.3 List of Data Sources


List of Tables


TABLE 1 Biodefense Market - Industry Summary & Critical Success Factors (CSFs)
TABLE 2 Biodefense market, by region, 2012 - 2020 (USD Million)
TABLE 3 U.S. biodefense market, by product, 2012 - 2020 (USD million)
TABLE 4 Biodefense - Key market driver analysis
TABLE 5 Biodefense - Key market restraint analysis
TABLE 6 Biological defense: Product pipeline
TABLE 7 List of pipeline products: Anthrax
TABLE 8 List of pipeline products: Smallpox
TABLE 9 List of pipeline products: Botulism
TABLE 10 List of pipeline products: Radiation/nuclear defense
TABLE 11 List of pipeline products: Other threats
TABLE 12 U.S. biodefense market, by product, 2012 - 2020 (USD Million)
TABLE 13 U.S. biodefense market, by scenario, 2012 - 2020 (USD Million)
TABLE 14 U.S. biodefense market, by source, 2012 - 2020 (USD Million)
TABLE 15 Programs under HHS:
TABLE 16 Programs under DoD:
TABLE 17 Programs under department of homeland security
TABLE 18 Programs under department of agriculture
TABLE 19 Canada biodefense market, by product, 2012 - 2020 (USD Million)
TABLE 20 Germany biodefense market, by product, 2012 - 2020 (USD Million)
TABLE 21 Biodefense program licensed manufacturing sites in the UK
TABLE 22 UK biodefense market, by product, 2012 - 2020 (USD Million)
TABLE 23 Japan biodefense market, by product, 2012 - 2020 (USD Million)
TABLE 24 China biodefense market, by product, 2012 - 2020 (USD Million)
TABLE 25 RoW biodefense market, by product, 2012 - 2020 (USD Million)
TABLE 26 Major list of biodefense contracts, by market player


List of Figures

FIG. 1 Biodefense: Market segmentation
FIG. 2 Global biodefense market, 2012 - 2020 (USD Million)
FIG. 3 Biodefense: Market dynamics
FIG. 4 Key opportunities prioritized
FIG. 5 Biodefense market - Porter's analysis
FIG. 6 Biodefense market - PESTEL analysis
FIG. 7 Biodefense market share by product, 2013 & 2020
FIG. 8 Global anthrax biodefense market, 2012 - 2020 (USD Million)
FIG. 9 Global smallpox biodefense market, 2012 - 2020 (USD Million)
FIG. 10 Global botulism biodefense market, 2012 - 2020 (USD Million)
FIG. 11 Global radiation/nuclear defense market, 2012 - 2020 (USD Million)
FIG. 12 Global biodefense market for other threats, 2012 - 2020 (USD Million)
FIG. 13 Biodefense market share by region, 2013 & 2020
FIG. 14 North America biodefense market , 2012 - 2020 (USD Million)
FIG. 15 U.S. biodefense market , 2012 - 2020 (USD Million)
FIG. 16 Canada biodefense market , 2012 - 2020 (USD Million)
FIG. 17 Europe biodefense market , 2012 - 2020 (USD Million)
FIG. 18 Germany biodefense market , 2012 - 2020 (USD Million)
FIG. 19 UK biodefense market , 2012 - 2020 (USD Million)
FIG. 20 Asia Pacific biodefense market , 2012 - 2020 (USD Million)
FIG. 21 Japan biodefense market , 2012 - 2020 (USD Million)
FIG. 22 China biodefense market , 2012 - 2020 (USD Million)
FIG. 23 RoW biodefense market , 2012 - 2020 (USD Million)